FDA refuses to file Advexin:
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The first-in-class gene therapy from Introgen gets a "refuse to file" letter from FDA due to an incomplete BLA, the firm announces Sept. 2. Advexin, a tumor suppressor cancer therapy that uses an adenoviral delivery system, was submitted in both the U.S. and Europe in June for treatment of recurrent, refractory head and neck cancer; the European Medicines Agency accepted the filing Aug. 18. Introgen declined to give details on the RTF letter, but said it is meeting with FDA to get more clarity and plans to appeal the action
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.